

(51) International Patent Classification:
C07K 16/28 (2006.01)(21) International Application Number:
PCT/US2021/031541(22) International Filing Date:
10 May 2021 (10.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/022,309 08 May 2020 (08.05.2020) US(71) Applicant: ELECTRA THERAPEUTICS, INC.
[US/US]; 681 Gateway Boulevard, 3rd Floor, South San Francisco, California 94080 (US).

(72) Inventors: PANICKER, Sandip; c/o Electra Therapeutics, Inc., 681 Gateway Boulevard, 3rd Floor, South San Francisco, California 94080 (US). ROSENTHAL, Adam David; c/o Electra Therapeutics, Inc., 681 Gateway Boulevard, 3rd Floor, South San Francisco, California 94080 (US). ROSE, Eileen Lingshu; c/o Electra Therapeutics, Inc., 681 Gateway Boulevard, 3rd Floor, South San Francisco, California 94080 (US).

(74) Agent: ROY, Madhuri et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SIRP ALPHA AND SIRP BETA 1 ANTIBODIES AND USES THEREOF

FIG. 1B

(57) Abstract: Provided herein are antibodies that bind signal regulatory protein SIRP α , SIRP β 1, or a combination of SIRP α and SIRP β 1, and methods of using such antibodies. In some embodiments, the antibodies are human monoclonal antibodies that bind human SIRP α and/or SIRP β 1. In some embodiments, the antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of myeloid cells, or a disease or condition associated with SIRP α and/or SIRP β 1 activity.